Intellia Therapeutics, Inc. (NTLA)
|Net Income (ttm)||-148.63M|
|Trading Day||July 26|
|Day's Range||132.00 - 140.00|
|52-Week Range||16.54 - 202.73|
It's a good time to be a gene-editing company.
Gene editing could revolutionize the way we treat diseases. Along the way, it could also create substantial opportunity for related stocks.
There are still some key unanswered questions for the biotech's promising gene-editing therapy.
Cathie Wood's genomics ETF is making big bets on the "Genomic Age."
After skyrocketing 68% last week, will this stock keep running higher?
Intellia Therapeutics (NTLA) CEO John Leonard believes that gene-editing therapy could come to market “very, very soon,” according to an interview on CNBC's Closing Bell, after news broke that CRISPR-ba...
After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed.
Genomics and gene editing is a sector that is truly in its infancy, but as we have seen this past week, that's not stopping investors from buying up companies in the sector at high valuations.
CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...
The trial success of CRISPR gene-editing technology has broad applications to treating other diseases, Intellia Therapeutics CEO John Leonard said.
Intellia Therapeutics - a gene-editing company co-founded by CRISPR pioneer and Nobel prize winner Jennifer Doudna - indicated that NTLA-2001, its experimental treatment for transthyretin amyloidosis pr...
In just the last few days, we got word of a healthcare game-changer that will save lives, eradicate much suffering and make investors money. The post This Healthcare Breakthrough Gives Me Chills appeare...
Intellia CEO on Crispr gene-editing treatment, secondary offering
Intellia Therapeutics president and CEO John Leonard joins 'Closing Bell' to discuss the clinical study of an experimental gene-editing treatment. The company also announced pricing of a secondary offer...
The stock price of Intellia Therapeutics, a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a stellar 70% rise in just two trading days, after the company announ...
The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a 4.1% drop over the last five trading days, afte...
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest Sci...
The company is about to fatten its coffers significantly.
Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia. The post Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to So...
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
How CRISPR gene editing will treat diseases in future: Nobel-winning Intellia co-founder Jennifer Doudna
Jennifer Doudna, 2020 Nobel Prize winner in chemistry for CRISPR gene editing and co-founder of Intellia Therapeutics, on future of the breakthrough technology.
Investors need to pay close attention to Intellia Therapeutics (NTLA) stock based on the movements in the options market lately.
Intellia Therapeutics Inc (NASDAQ: NTLA) has priced a previously announced public offering at $145 per share, representing a discount of 4.4% from the last close price of $151.6 on Tuesday. The company ...
New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?
CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...
There's lots of good news to talk about today, but one of the biggest stories came from a major healthcare play. Let's dive in.
Intellia (NTLA) posts positive interim data from phase I study on lead genome-editing candidate NTLA-2001 being developed for treating transthyretin (ATTR) amyloidosis. Stock up.
Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.
Intellia Therapeutics Inc (NASDAQ: NTLA) commenced an underwritten public offering of $400 million shares of its common stock. Underwriters have an option to purchase up to an additional 15% of the sha...
An SVB Leerink genetic medicine analyst is bullish on shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA). Here's why.
CAMBRIDGE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...
Investors may want to closely monitor the results of a phase 3 clinical trial of Merck & Co. Inc.'s ( MRK , Financial) pill designed to protect patients from Covid-19's most severe health impact. Result...
Early data is very promising: Biotech analyst on CRISPR technology
Intellia is soaring after promising trial results using CRISPR technology. Alethia Young, Cantor Fitzgerald senior biotech analyst, joins 'Closing Bell' to discuss the significance of the trial and what...
As a result of this news, NTLA stock is way up, and other genome editing stocks are seeing gains as well. The post Intellia Makes a Splash, Bringing Other CRISPR Stocks Along for the Ride appeared first...
Find out why these stocks are climbing higher.
Intellia soars on trial results using CRISPR technology
CNBC's Meg Tirrell reports on the promising results from a trial using CRISPR gene-editing technology, which sent shares of Intellia higher.
The company reported promising interim trial results for its CRISPR gene-editing candidate.
The shares of biotechnology name Intellia Therapeutics Inc (NASDAQ:NTLA) are soaring this morning, up 48% to trade at $131.92 at last check -- earlier hitting a record high of $144.39 -- after positive ...
So what will the stock market do today? All eyes are on gene-editing stocks like NTLA and on recovering crypto prices.
Intellia Therapeutics Inc (NASDAQ: NTLA) said on Saturday its clinical trial that used Crispr technology to treat a genetic disorder inside the human body showed positive results. The biotech company ha...
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. What Happened: Intellia and Regeneron Ph...
Gene editing stocks are getting a boost on Monday morning after Intellia Therapeutics said it was successful using CRISPR gene-editing therapy directed inside the body to an internal organ. The post Gen...
Intellia shares jump on positive gene-editing data
Shares of Intellia Therapeutics were soaring pre-market Monday. The company announced positive data from a clinical study of an experimental gene-editing treatment.
Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced positive interim data from an ongoing Phase 1 study of NTLA-2001, which is being developed as a s...
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single...
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June 26, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim data ...
Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology...
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone (NYSE: BX) announced today that funds managed by Blackstone Life Sciences have committed $250 million towards the launch of a new autologous and allogeneic ...
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 ... [Read more...]
|IPO Date |
May 6, 2016
|Stock Exchange |
|Ticker Symbol |
In 2020, NTLA's revenue was $57.99 million, an increase of 34.55% compared to the previous year's $43.10 million. Losses were -$134.23 million, 34.9% more than in 2019.
According to 14 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is 138.44, which is an increase of 3.31% from the latest price.